LDL Receptor Gene-ablated Hamsters

A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis

Xin Guo, Mingming Gao, Yunan Wang, Xiao Lin, Liu Yang, Nathan Cong, Xiangbo An, Feng Wang, Kai Qu, Liqing Yu, Yuhui Wang, Jinjie Wang, Haibo Zhu, Xunde Xian, George Liu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease caused mainly by LDL receptor (Ldlr) gene mutations. Unlike FH patients, heterozygous Ldlr knockout (KO) mice do not show a dominant FH trait. Hamsters, like humans, have the cholesteryl ester transfer protein, intestine-only ApoB editing and low hepatic cholesterol synthesis. Here, we generated Ldlr-ablated hamsters using CRISPR/Cas9 technology. Homozygous Ldlr KO hamsters on a chow diet developed hypercholesterolemia with LDL as the dominant lipoprotein and spontaneous atherosclerosis. On a high-cholesterol/high-fat (HCHF) diet, these animals exhibited severe hyperlipidemia and atherosclerotic lesions in the aorta and coronary arteries. Moreover, the heterozygous Ldlr KO hamsters on a short-term HCHF diet also had overt hypercholesterolemia, which could be effectively ameliorated with several lipid-lowering drugs. Importantly, heterozygotes on 3-month HCHF diets developed accelerated lesions in the aortas and coronary arteries.Our findings demonstrate that the Ldlr KO hamster is an animal model of choice for human FH and has great potential in translational research of hyperlipidemia and coronary heart disease.

Original languageEnglish (US)
JournalEBioMedicine
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Hyperlipoproteinemia Type II
LDL Receptors
Nutrition
Cricetinae
Coronary Artery Disease
Rodentia
Genes
Diet
High Fat Diet
Cholesterol
Fats
Hypercholesterolemia
Hyperlipidemias
Aorta
Coronary Vessels
Animals
Clustered Regularly Interspaced Short Palindromic Repeats
Cholesterol Ester Transfer Proteins
Inborn Genetic Diseases
Translational Medical Research

Keywords

  • Atherosclerosis
  • CRISPR/Cas9
  • Golden Syrian hamster
  • Hyperlipidemia
  • LDL receptor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

LDL Receptor Gene-ablated Hamsters : A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis. / Guo, Xin; Gao, Mingming; Wang, Yunan; Lin, Xiao; Yang, Liu; Cong, Nathan; An, Xiangbo; Wang, Feng; Qu, Kai; Yu, Liqing; Wang, Yuhui; Wang, Jinjie; Zhu, Haibo; Xian, Xunde; Liu, George.

In: EBioMedicine, 01.01.2017.

Research output: Contribution to journalArticle

Guo, Xin ; Gao, Mingming ; Wang, Yunan ; Lin, Xiao ; Yang, Liu ; Cong, Nathan ; An, Xiangbo ; Wang, Feng ; Qu, Kai ; Yu, Liqing ; Wang, Yuhui ; Wang, Jinjie ; Zhu, Haibo ; Xian, Xunde ; Liu, George. / LDL Receptor Gene-ablated Hamsters : A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis. In: EBioMedicine. 2017.
@article{75a73ac55e204144a165f6bee36e34aa,
title = "LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis",
abstract = "Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease caused mainly by LDL receptor (Ldlr) gene mutations. Unlike FH patients, heterozygous Ldlr knockout (KO) mice do not show a dominant FH trait. Hamsters, like humans, have the cholesteryl ester transfer protein, intestine-only ApoB editing and low hepatic cholesterol synthesis. Here, we generated Ldlr-ablated hamsters using CRISPR/Cas9 technology. Homozygous Ldlr KO hamsters on a chow diet developed hypercholesterolemia with LDL as the dominant lipoprotein and spontaneous atherosclerosis. On a high-cholesterol/high-fat (HCHF) diet, these animals exhibited severe hyperlipidemia and atherosclerotic lesions in the aorta and coronary arteries. Moreover, the heterozygous Ldlr KO hamsters on a short-term HCHF diet also had overt hypercholesterolemia, which could be effectively ameliorated with several lipid-lowering drugs. Importantly, heterozygotes on 3-month HCHF diets developed accelerated lesions in the aortas and coronary arteries.Our findings demonstrate that the Ldlr KO hamster is an animal model of choice for human FH and has great potential in translational research of hyperlipidemia and coronary heart disease.",
keywords = "Atherosclerosis, CRISPR/Cas9, Golden Syrian hamster, Hyperlipidemia, LDL receptor",
author = "Xin Guo and Mingming Gao and Yunan Wang and Xiao Lin and Liu Yang and Nathan Cong and Xiangbo An and Feng Wang and Kai Qu and Liqing Yu and Yuhui Wang and Jinjie Wang and Haibo Zhu and Xunde Xian and George Liu",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ebiom.2017.12.013",
language = "English (US)",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - LDL Receptor Gene-ablated Hamsters

T2 - A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis

AU - Guo, Xin

AU - Gao, Mingming

AU - Wang, Yunan

AU - Lin, Xiao

AU - Yang, Liu

AU - Cong, Nathan

AU - An, Xiangbo

AU - Wang, Feng

AU - Qu, Kai

AU - Yu, Liqing

AU - Wang, Yuhui

AU - Wang, Jinjie

AU - Zhu, Haibo

AU - Xian, Xunde

AU - Liu, George

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease caused mainly by LDL receptor (Ldlr) gene mutations. Unlike FH patients, heterozygous Ldlr knockout (KO) mice do not show a dominant FH trait. Hamsters, like humans, have the cholesteryl ester transfer protein, intestine-only ApoB editing and low hepatic cholesterol synthesis. Here, we generated Ldlr-ablated hamsters using CRISPR/Cas9 technology. Homozygous Ldlr KO hamsters on a chow diet developed hypercholesterolemia with LDL as the dominant lipoprotein and spontaneous atherosclerosis. On a high-cholesterol/high-fat (HCHF) diet, these animals exhibited severe hyperlipidemia and atherosclerotic lesions in the aorta and coronary arteries. Moreover, the heterozygous Ldlr KO hamsters on a short-term HCHF diet also had overt hypercholesterolemia, which could be effectively ameliorated with several lipid-lowering drugs. Importantly, heterozygotes on 3-month HCHF diets developed accelerated lesions in the aortas and coronary arteries.Our findings demonstrate that the Ldlr KO hamster is an animal model of choice for human FH and has great potential in translational research of hyperlipidemia and coronary heart disease.

AB - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease caused mainly by LDL receptor (Ldlr) gene mutations. Unlike FH patients, heterozygous Ldlr knockout (KO) mice do not show a dominant FH trait. Hamsters, like humans, have the cholesteryl ester transfer protein, intestine-only ApoB editing and low hepatic cholesterol synthesis. Here, we generated Ldlr-ablated hamsters using CRISPR/Cas9 technology. Homozygous Ldlr KO hamsters on a chow diet developed hypercholesterolemia with LDL as the dominant lipoprotein and spontaneous atherosclerosis. On a high-cholesterol/high-fat (HCHF) diet, these animals exhibited severe hyperlipidemia and atherosclerotic lesions in the aorta and coronary arteries. Moreover, the heterozygous Ldlr KO hamsters on a short-term HCHF diet also had overt hypercholesterolemia, which could be effectively ameliorated with several lipid-lowering drugs. Importantly, heterozygotes on 3-month HCHF diets developed accelerated lesions in the aortas and coronary arteries.Our findings demonstrate that the Ldlr KO hamster is an animal model of choice for human FH and has great potential in translational research of hyperlipidemia and coronary heart disease.

KW - Atherosclerosis

KW - CRISPR/Cas9

KW - Golden Syrian hamster

KW - Hyperlipidemia

KW - LDL receptor

UR - http://www.scopus.com/inward/record.url?scp=85039149558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039149558&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2017.12.013

DO - 10.1016/j.ebiom.2017.12.013

M3 - Article

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -